Displaying drugs 14101 - 14125 of 14342 in total
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
Experimental
PAS219
Experimental
FR239087
Experimental
4-Fluorophenethyl Alcohol
Experimental
Phenacetin
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
1,3,5-trichlorobenzene
Experimental
(P-Iodophenylacetylamino)Methylphosphinic Acid
Experimental
1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea
Experimental
N-(Chlorophenyl)-N'-hydroxyguanidine
Experimental
(R)-4-Nitrostyrene oxide
Experimental
SC45647
Experimental
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
Cannabinor
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
Indisulam
Investigational
1-[4-(hydroxymethyl)phenyl]guanidine
Experimental
Displaying drugs 14101 - 14125 of 14342 in total